Allarity advances stenoparib with Phase 3 manufacturing, targeting FDA approval for ovarian cancer.

Allarity Therapeutics is progressing with Phase 3 manufacturing of stenoparib, a dual PARP and WNT pathway inhibitor, aiming to complete by Q3 2026. This step supports a pivotal trial for advanced ovarian cancer, leveraging FDA Fast Track designation to accelerate approval. The company has completed all manufacturing payments and expects no further costs. Ongoing Phase 2 trials continue enrolling patients, with plans to advance toward pivotal-stage clinical development soon.